All In Biotech

NDA 019618 · Mylan Speciality Lp

Rowasa

Mesalamine · Rectal · Aminosalicylate

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Dec 24, 1987

Approved uses

1

Original approval plus efficacy supplements

Registered trials

188

77 Phase 3, 14 recruiting

FAERS reports

28,157

24,946 serious, 1,988 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 3, 2026.

ROWASA is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. ROWASA is an aminosalicylate indicated for treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. ( 1 )

Mechanism: The mechanism of action of 5-ASA (mesalamine) is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids), and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids) is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 24, 1987 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • ROWASA · MESALAMINE 4GM/60ML · ENEMA, RECTAL · Prescription · TE AB
  • SFROWASA · MESALAMINE 4GM/60ML · ENEMA, RECTAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6,489
  • colitis ulcerative4,631
  • drug ineffective4,453
  • condition aggravated3,401
  • diarrhoea2,667
  • haematochezia2,486
  • fatigue2,255
  • abdominal pain2,185
  • weight decreased1,956
  • headache1,910
  • nausea1,884
  • pyrexia1,834

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004126
2005167
2006120
2007167
2008581
2009136
2010281
2011713
2012628
2013180
2014226
2015284
2016338
2017372
2018596
2019736
20201,165
20212,427
20224,173
20234,308
20244,045
20253,998
20262,389

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rowasa (Mesalamine W/Cleansing Wipes)

2024 spending

$44K

Beneficiaries

n/a

17 claims

Per beneficiary

n/a

$370.00 per unit

View as table
YearSpending
2020$335,019
2021$92,430
2022$75,415
2023$69,155
2024$44,029

Part D: Sfrowasa (Mesalamine)

2024 spending

$32K

Beneficiaries

12

17 claims

Per beneficiary

$2,665

$0.89 per unit

View as table
YearSpending
2020$53,872
2021$73,510
2022$78,421
2023$29,711
2024$31,979

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 265 on PubMed

Sponsor: Mylan Speciality Lp · Also marketed as Sfrowasa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.